Hypothesis

Age‑related increases in gut‑derived phenylacetic acid (PA) drive endothelial senescence, blood‑brain barrier (BBB) leakage, and vagal afferent dysfunction, thereby causing microglial activation and cognitive decline. Selective inhibition of the microbial phenylacetate‑CoA ligase that produces PA will lower circulating PA, restore BBB integrity, improve vagal signaling, and ameliorate brain aging phenotypes without requiring broad microbiome changes or SCFA restoration.

Mechanistic Rationale

Phenylacetic acid accumulates in aged mice and humans due to shifted microbial aromatic amino acid metabolism (3). PA enters the circulation, crosses a compromised BBB, and induces endothelial cell senescence via HDAC inhibition and increased VCAM‑1 expression, promoting leukocyte adhesion and further barrier breakdown (3). Senescent endothelial cells amplify microglial ROS production and innate immune activation (1). Concurrently, PA disrupts vagal afferent signaling by activating GPR84 on PHOX2B+ enteric neurons, reducing interoceptive input to the hippocampus and impairing memory engram formation (4, 5).

If PA is a primary upstream effector, lowering its production should protect the endothelium and vagal fibers, thereby breaking the gut→brain aging cascade even if the overall microbiota composition remains aged.

Testable Predictions

1. Metabolite level – Aged mice treated with a phenylacetate‑CoA ligase inhibitor will show a ≥40 % reduction in plasma PA compared with vehicle‑treated aged controls, while total SCFA concentrations remain unchanged.
2. BBB integrity – Inhibitor‑treated mice will exhibit decreased Evans blue extravasation and lower circulating CSF/plasma albumin ratio, indicating restored BBB tightness.
3. Endothelial senescence – Brain microvessels from inhibitor‑treated mice will have reduced SA‑β‑gal activity and VCAM‑1 immunostaining relative to controls.
4. Vagal signaling – Electrophysiological recordings of vagal afferent firing in response to gut distension will be increased, and hippocampal c‑Fos activation after vagal stimulation will be restored.
5. Neuroinflammation & cognition – Microglial Iba1 density and ROS production will be lowered, and performance in novel object recognition and Morris water maze will improve to levels comparable with young mice.
6. Specificity – Fecal microbiota transplantation from inhibitor‑treated aged donors into germ‑free young recipients will not transfer the protective phenotype, confirming that the effect is mediated by PA reduction rather than broader microbial shifts.

Experimental Design

• Subjects: 20‑month‑old C57BL/6J mice (n=10 per group).
• Intervention: Oral administration of a specific phenylacetate‑CoA ligase inhibitor (validated in vitro) daily for 8 weeks; control groups receive vehicle.
• Groups: (1) Aged + vehicle, (2) Aged + inhibitor, (3) Young + vehicle (baseline), (4) Aged + inhibitor + GPR84 antagonist (to test additive vagal rescue).
• Readouts: Plasma PA (LC‑MS/MS), BBB permeability (Evans blue, albumin ratio), endothelial senescence (SA‑β‑gal, VCAM‑1), vagal afferent activity (in vivo electrophysiology), microglial activation (Iba1, ROS), cognitive assays (novel object recognition, Morris water maze).
• Statistical analysis: ANOVA with post‑hoc Tukey; significance set at p<0.05.

Potential Outcomes and Interpretation

• If predictions hold: The data would support PA as a causal mediator of gut‑driven brain aging, demonstrating that targeting a single microbial metabolite can rescue BBB and vagal function, thereby ameliorating neuroinflammation and cognition. This would shift therapeutic focus from broad microbiome remodeling to precise metabolite inhibition.
• If PA reduction fails to improve BBB or cognition despite lowering PA: The hypothesis would be falsified, suggesting that PA is a biomarker rather than a driver, or that additional metabolites (e.g., MCFAs, TMAO) are required for the pathogenic cascade.
• If BBB improves but vagal signaling and cognition do not: This would indicate that endothelial protection is necessary but insufficient, emphasizing the need to concurrently restore vagal afferent integrity.

By providing a clear, falsifiable route to test whether a single gut‑derived metabolite sets the brain’s aging trajectory, this hypothesis advances the bottom‑up view of the gut‑brain axis and proposes a concrete, mechanism‑based intervention strategy for age‑related cognitive decline.